2023-09-13 ブラウン大学
◆研究チームは、cis P-tauを妊娠合併症である子癇前症の患者の血液と胎盤で同定し、マウスモデルでcis P-tauを減少させると、子癇前症の症状が改善することを発見しました。この研究は、子癇前症の早期診断と治療における新しい手法を提供し、cis P-tauをターゲットとした治療法が子癇前症の患者にとって有用である可能性があることを示しています。
<関連情報>
- https://www.brown.edu/news/2023-09-13/preeclampsia-tau
- https://www.nature.com/articles/s41467-023-41144-6
シスP-タウは、子癇前症の中心的な循環および胎盤の病因ドライバーであり、治療標的である。 Cis P-tau is a central circulating and placental etiologic driver and therapeutic target of preeclampsia
Sukanta Jash,Sayani Banerjee,Shibin Cheng,Bin Wang,Chenxi Qiu,Asami Kondo,Jan Ernerudh,Xiao Zhen Zhou,Kun Ping Lu & Surendra Sharma
Nature Communications Published:05 September 2023
DOI:https://doi.org/10.1038/s41467-023-41144-6
Abstract
Preeclampsia (PE) is the leading cause of maternal and fetal mortality globally and may trigger dementia later in life in mothers and their offspring. However, the etiological drivers remain elusive. Cis P-tau is an early etiological driver and blood biomarker in pre-clinical Alzheimer’s and after vascular or traumatic brain injury, which can be targeted by stereo-specific antibody, with clinical trials ongoing. Here we find significant cis P-tau in the placenta and serum of PE patients, and in primary human trophoblasts exposed to hypoxia or sera from PE patients due to Pin1 inactivation. Depletion of cis P-tau from PE patient sera by the antibody prevents their ability to disrupt trophoblast invasion and endovascular activity and to cause the PE-like pathological and clinical features in pregnant humanized tau mice. Our studies uncover that cis P-tau is a central circulating etiological driver and its stereo-specific antibody is valuable for early PE diagnosis and treatment.
